United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
GAITHERSBURG, Md., Jan. 26, 2016 -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the BIO CEO & Investor Conference to be held February 8 - 9, 2016 in New York, NY.
Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Monday, February 8, 2016 at 8:00 a.m. ET.
About Altimmune
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.
The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.
Contacts: Bill Enright President and CEO Phone: 240-654-1450 Email: [email protected] Investor Relations Stephanie Carrington ICR, Inc. Phone: 646-277-1282 Email: [email protected]
